Hydrofarm Regains Nasdaq Equity Compliance After Debt Restructuring

Hydrofarm Holdings Group announced on November 12, 2026 that Nasdaq had confirmed in a letter dated November 9, 2026 that the company regained compliance with Listing Rule 5550(b)(1), the $2.5 million minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market.

Nasdaq’s confirmation followed its review of the restructuring transactions completed in October. Hydrofarm said it would monitor its stockholders’ equity and other continued-listing requirements, including the minimum bid-price requirement in Listing Rule 5550(a)(2), and take actions it considers necessary to regain or maintain compliance.

The compliance chronology in Hydrofarm’s October 27, 2026 securities filing begins with an April 1, 2026 letter from Nasdaq’s Listing Qualifications Department notifying the company that it did not meet the equity requirement. Nasdaq granted an extension on June 16, 2026 after reviewing Hydrofarm’s compliance plan, then notified the company on July 2, 2026 that it had not met the extension’s terms. Hydrofarm requested a hearing on July 9, 2026, staying further Nasdaq action during the hearing process. Following the hearing, the Nasdaq Hearings Panel set an October 16, 2026 deadline to demonstrate compliance and later extended it to October 27, 2026.

On that final deadline, Hydrofarm terminated its senior secured term loan and completed a registered direct offering and concurrent private placement. The filing put the loan’s outstanding principal at approximately $109 million as of September 30, 2026. Hydrofarm said the transactions eliminated its outstanding debt, except for an immaterial amount of other debt comprising a foreign subsidiary’s revolving line of credit and mortgage, and restored positive stockholders’ equity.

Hydrofarm’s earlier compliance position was based on an unaudited pro forma balance sheet giving effect to those transactions. The company said it showed stockholders’ equity above the required minimum and that it believed Hydrofarm had regained compliance when the October filing was made. The same filing acknowledged that the company remained subject to panel review and Nasdaq monitoring, leaving the November letter as the subsequent confirmation of that position.

Chairman and Chief Executive Officer Bill Toler called the confirmation another milestone in the financial restructuring and identified management’s operating priorities: “With this confirmation, our organization is focused on profitable growth: our proprietary brands out of Eugene, the direct commercial sales channel that opened when the term loan was eliminated, and scaling logistics services under Project Agility.”

Hydrofarm cautioned that another equity-rule deficiency during the Mandatory Panel Monitor period would not provide another compliance plan or cure period and could result in delisting. During the earlier process, the company received an extension and then a hearing stay; during panel monitoring, another equity deficiency would not offer that same route to a cure.

Hydrofarm’s remaining listing work centers on maintaining the equity position established by the restructuring and satisfying the separate bid-price standard under ongoing Nasdaq oversight.